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ABSTRAK 
 
Pengesanan DNA-HPV di Dalam Kikisan Servik dan Uretra Menggunakan Hybrid 
Capture 2 dan Nested-PCR dan Kaitannya dengan Sitomorfologi. 
 
 
Jangkitan virus papilloma manusia (HPV) adalah agen penyebab kepada 
pertumbuhan kanser servik. Kajian ini bertujuan untuk mengesan kehadiran HPV pada 
pap smear wanita yang menghadiri pemeriksaan rutin di Hospital Kota Bharu, Hospital 
Universiti Sains Malaysia dan Hospital Kuala Terengganu. Sampel serviks dari setiap 
wanita dalam dua bentuk (split-sampling); Pap smear konvensional (CP) dan Pap smear 
ThinPrep® (TP). Wanita ini diberikan boring soal selidik untuk menentukan faktor risiko 
untuk pertumbuhan kanser serviks. Pasangan laki-laki dijemput untuk memberikan 
kikisan uretra untuk kajian HPV. Sample serviks dan uretra diuji dengan Hybrid Capture 
2 (HR-HC2) dan tindak balas berantai polymerase (nested-PCR). Keputusan HPV di 
dalam kikisan serviks dikaitkan dengan diagnosis sitologi dari CP dan TP.  
 
Sebanyak 705 kikisan serviks dan 99 kikisan uretra laki-laki dikumpulkan. 702 sampel 
serviks mempunyai keputusan penilaian sitologi untuk kedua-dua CP dan TP. Dari CP, 
92.7% sampel kikisan serviks adalah normal, 2% adalah tidak normal Pap smear 
manakala 5.3% smear tidak memuaskan untuk penilaian sitologi. Dengan TP, 87.1% 
adalah normal, 1.7% adalah tidak normal dan 11.1% tidak memuaskan untuk penilaian 
sitologi. Keputusan diagnosis Pap smear secara konvensional dan ThinPrep® adalah 
sama sebanyak 88.9%. Kecukupan untuk pesampelan dengan TP (88.9%) adalah 
setanding dengan CP (94.7%).  
 
 xix
635 sampel serviks adalah mencukupi untuk ujian HPV. 44 (6.9%) sampel positif untuk 
HPV; 27 dengan HR-HC2 dan 28 dengan nested-PCR. Yang terakhir ini lebih sensitif 
untuk mengesan HPV; dengan sensitiviti 72.7% dibandingkan dengan sensitiviti HR-
HC2; 36.4%, sedangkan spesifisiti adalah sama, 96.8% dan 96.3%. Pengesanan HPV 
meningkat apabila diagnosis sitologi dari Pap smear ThinPrep® (TP) digunakan sebagai 
standard. Genotip dari 21/28 (75.0%) nested-PCR HPV positif sampel adalah; HPV-16 
(57.1%), HPV-58 (19.0%), HPV-6 (9.5%) dan HPV-18, -33 dan -61 (4.8%).  
 
Kehadiran HPV-DNA dikesan di semua lesion termasuk 'Dalam Batas Normal' (5.4%) 
dan 'Tidak memuaskan untuk Evaluasi' didiagnosis (11.7%) oleh CP dan 5.1% dan 
10.8% masing-masing oleh TP. HPV dikesan dalam semua kes didiagnosis sitologi 
sebagai HGSIL (1 kes) dan kanser (3 kes). Untuk LGSIL didiagnosis oleh CP, 50.0% 
mempunyai HPV dan 57.1% di dalam TP. Kajian ini menunjukkan ujian HPV lebih 
sensitif berbanding sitologi untuk mengesan HPV. 
 
99 pasangan laki-laki memberikan kikisan uretra secara sukarela untuk ujian HPV. 10 
sampel mempunyai tahap DNA yang mencukupi untuk analisis, tidak ada yang positif 
untuk HPV. 
 
Kaji selidik analisis tidak menunjukkan sebarang faktor risiko yang signifikan dalam 
semua subjek. 
 
 
 xx
ABSTRACT 
 
 
 Detection of HPV-DNA in Cervical and Urethral Scrapings using  
Hybrid Capture 2 and nested-PCR and Their Correlation with Cytomorphology  
 
Human papillomavirus (HPV) infection is a causative agent for development of cervical 
cancer. This study aims to detect the presence of HPV in routine pap smears of women 
who attended Hospital Kota Bharu, Hospital Universiti Sains Malaysia and Hospital 
Kuala Terengganu. The cervical sample from each woman was in two forms (split 
sampling); conventional smear (CP) and ThinPrep® smear (TP). These women were 
given a questionnaire to determine the risk factors for cervical cancer development. The 
male spouses were invited to provide urethral scrapings for HPV studies. The cervical 
and urethral samples were subjected to Hybrid Capture 2 and nested-PCR. HPV results 
of the cervical scrapings were correlated with cytological diagnosis from CP and TP.  
 
A total of 705 cervical scrapings and 99 male urethral scrapings were collected. 702 
cervical samples were available for both CP and TP cytological evaluation. By CP, 
92.7% of the collected cervical scrapings had normal smear, 2.0% had abnormal smear 
and 5.3% smears were unsatisfactory for evaluation. By TP, 87.1% was normal, 1.7% 
was abnormal and 11.1% was unsatisfactory for evaluation. The diagnoses of the 
conventional Pap smears and ThinPrep® Pap smears were 88.9% in agreement. The 
adequacy of sampling by TP (88.9%) is comparable to CP (94.7%). 
  
 
 xxi
635 cervical samples were sufficient for HPV testing. 44 (6.9%) samples were positive 
for HPV; 27 by HR-HC2 and 28 by nested-PCR. The latter is more sensitive to detect 
HPV; 72.7% of sensitivity compared to HR-HC2; 36.4% sensitivity while the specificity 
is fairly similar; 96.8% and 96.3%.  HPV detection improved when cytological diagnosis 
from ThinPrep® smear (TP) was used as gold standard. The genotypes of the 21/28 
(75.0%) nested-PCR HPV positive samples were; HPV-16 (57.1%), HPV-58 (19.0%), 
HPV-6 (9.5%) and HPV-18, -33 and -61 (4.8%).   
 
HPV-DNA was seen in all lesions including ‘Within Normal Limit’ (5.4%) and 
‘Unsatisfactory for Evaluation’ (11.7%) diagnosed by CP and 5.1% and 10.8% 
respectively  by TP. HPV was detected in all cases diagnosed cytologically as HGSIL (1 
case) and cancer (3 cases). For LGSIL diagnosed by CP, 50.0% had HPV and by TP 
57.1%.  This study shows HPV testing is more sensitive than cytology in detecting 
HPVs.   
 
99 male spouses volunteered the urethral scrapings for HPV testing. 10 samples had 
adequate level of DNA for analysis, none was found to be HPV positive. 
 
Questionnaire survey analysis did not show any significant risk factor in all subjects.  
  
 
 
 xxii
 1
CHAPTER ONE 
INTRODUCTION AND REVIEW OF LITERATURE 
 
1.0 Introduction 
 
Cervix is an organ of the female reproductive system. It is located at the 
lower part of the uterus (womb) and is lined by a protective stratified squamous 
epithelium. Endocervix is part of the cervix that is closest to the body of uterus 
whereas ectocervix is part of the cervix next to the vagina. Cervical cancer 
commonly starts at where these 2 parts meet and occurs when the normal cells keep 
dividing. These cells also infiltrate and proliferate to become malignant abnormal 
cells. They reproduce in the epithelium and spread to adjacent stromal tissues and 
supporting muscles in the cervix. Cervical cancer does not form suddenly but 
gradually develop from a precancerous stage that turn into cancer at a later time.   
 
Several terms had been used to describe the precancerous changes that occur 
in the cervix. These include cervical intraepithelial neoplasia (CIN), squamous 
intraepithelial lesion (SIL) and dysplasia. The Bethesda system has been introduced 
in order to uniform the nomenclature for abnormal cytology report. There are two 
types of cervical cancer, namely squamous cell carcinoma (SCC) and 
adenocarcinoma (ADC). SCC is the most common and develops from the squamous 
metaplastic cells on the surface of the cervix. ADC is uncommon and they develop 
from the glands in the endocervical canal. Cervical cancer is nearly always fatal if it 
is not detected and treated early.  
 2
It is commonly accepted that the development of almost all cervical cancers 
are associated with human papillomavirus (HPV) (Malik, 2005, Steenbergen et al., 
2005). Their association was first postulated by Harald zur Hausen in 1970s. It was 
suggested that HPV-16 and HPV-18 could play a role in cervical cancer based on 
specimens that these authors were studying (zur Hausen, 2002). HPV is a sexually 
transmitted infection (STI) that is very common among young men and women in 
many parts of the world. It is asymptomatic in nature and had a long incubation 
period. They become highly prevalent and infection could be easily and unknowingly 
transmitted (Tovar et al., 2008). Women are at an increased risk of developing severe 
dysplasia and cervical cancer if infected with certain oncogenic type of the virus. The 
most common (and benign) symptomatic presentation of an HPV infection is genital 
warts (Condyloma acuminatum) – a wart that occurs on the genitalia. Other visible 
HPV infections are the plantar warts (Verruca pedis) – usually only found on 
pressure points on the soles of the feet and the common warts (Verruca vulgaris) – 
most common on hands but can grow anywhere on the body. All are curable, but 
evidence suggests that the virus persists in the tissue for a long period of time and 
can develop into cancer (Schiffman and Castle, 2003). 
 
The incidence and mortality rates of cervical cancer have been drastically 
reduced since the introduction of cervical cancer screening programs. Over the past 5 
decades, cervical cytology becomes the major screening program worldwide. The 
conventional Papanicolaou test and the newer liquid-based cytology (LBC) 
techniques had allowed an early detection of cervical abnormalities prior to the 
development of invasive cervical cancer.  
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HPV testing has now been incorporated (as primary or secondary test) into 
screening programs that previously relied only on cytology (Burd, 2003). Some HPV 
tests such as Hybrid Capture and a variety of Polymerase Chain Reaction protocols 
(using consensus or specific primer) have been implemented in developed countries. 
Both assays are suitable for high-throughput testing and automated execution of the 
result. The identification of specific HPV genotypes can be achieved (at high degree 
of resolution) by a variety of methods, which may be more or less comprehensive in 
their number of detectable HPV types, including Southern and Northern blot, dot blot 
or DNA sequencing (Brestovac et al., 2005).  
 
HPV tests allowed an early identification of populations at different risk 
levels for this neoplasia since HPV infection is a “necessary cause” of cervical 
cancer (de Lang and Wilander, 2005, Fontaine et al., 2007). It is also more sensitive 
for the detection of high-risk group of HPV in cervical lesions than cytology (De 
Francesco et al., 2008). Furthermore, it shows encouraging results when used in 
conjunction with cytological analysis in women 30 years of age or older. It is also 
recommended for most women with equivocal findings on cervical cytological 
analysis (atypical squamous cells of undetermined significance, or ASCUS) 
(Schiffman and Solomon, 2003). 
 
There are some factors that had been identified (based on experience in 
developed countries) which can significantly reduce the number of new cases of 
cervical cancer and the mortality rate associated with it. It has been shown that high 
coverage, well planned and organized screening programs, general awareness about 
cervical cancer and the improvement of existing health care services can reduce the 
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burden of cervical cancer for women and for the health care system. As detailed by 
Cuzick et al. (2008), cost, performance (accuracy and reproducibility), coverage and 
acceptability, infrastructural requirements, and complexity of technology and 
implementation (i.e., number of visits required to effect treatment) are very important 
factors in reducing the incidence of disease.  
 
The introduction of currently licensed HPV vaccines - Gardasil® (Merck & 
Co., Inc., Whitehouse Station, NJ USA); quadrivalent (HPV types 6, 11, 16, and 18) 
and CervarixTM (GlaxoSmithKline Biologicals, Rixensart, Belgium); bivalent (HPV 
types 16, and 18) may prevent the transmission of this virus (Zonfrillo and Hackley, 
2008, Ronco et al., 2006). However, it does not replace routine cervical cancer 
screening because vaccines do not protect against all HPV types. Furthermore, it 
cannot be assured that the women are automatically protected against the virus. They 
are also not cost effective for developing countries (Zimet et al., 2008). The 
probability of getting HPV infection remains high and population are prone to 
develop cervical cancer. The secondary prevention by screening and treatment will 
continue to be crucially important in cervical cancer prevention program especially 
through the detection, treatment and follow-up of its precursors (Denny, 2005).  
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1.0.1 Justification of the study 
 
This study is expected to provide information on the cervical cancer 
screening program that compares conventional cytology and liquid-based cytology 
using split-sampling technique and HPV testing. Liquid-based cytology had been 
used worldwide as a replacement of conventional Pap smear in order improve quality 
of smear and getting better cytomorphological diagnosis. 
  
The association of HPV and development of cervical intraepithelial changes 
had been widely studied. HPV testing had been incorporated in cervical cancer 
screening as adjunctive to Pap smear or standalone test in developed countries. Due 
to this reason, this study is expected to give the statistically significant difference 
between HPV testing and cytology result. HPV testing either using HC2 or PCR is 
expected to sensitively detect HPV infection in women. Thus, HPV testing should 
also be included as early preventive method of cervical cancer instead of cytology in 
Malaysia. 
 
Besides, limited data on epidemiological distribution of HPV infection 
among Malaysian women should get an attention. Furthermore, no study regarding 
HPV infection in men had been reported. The present results are expected to provide 
a database of HPV infection distribution in the study area.  Early detection of HPV 
makes it possible to avoid development of pre-cancerous stage and invasive cancer in 
the future. 
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1.0.2 Rationale of doing the study 
 
Study on HPV infection in Malaysia is very limited. The use of HC2 (the 
only FDA approved HPV test) in detecting HPV infection in Malaysia still not 
widely practised. There are only 6 HC2 DML units installed in Malaysia; 2 are for 
research purposes only (in HUSM and HUKM) while another 4 are in the private 
sector (all located at Federal territory and Selangor).  
 
So far, HPV testing has not yet been provided at Malaysian government 
hospitals. Very few clinicians know and are aware about HPV testing and their role 
in helping early detection of the development of cervical cancer. There is no record 
of studies conducted in Malaysia describing the significant usage of HPV testing and 
cytology (current screening tool of cervical cancer). Therefore a robust study needs 
to be done to determine the performances of these HPV tests and to determine the 
differences between it and cytological diagnosis. Furthermore, data epidemiological 
distribution of HPV infection is needed in order to implement the usage of HPV 
vaccine among Malaysian in the future.   
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1.1 Cervical Cancer Burden 
 
Cervical cancer is the most common cause of cancer death among women in 
developing countries and remains second only to breast cancer worldwide (Figure 
1.1). An estimated 2329.08 million women ages 15 years and older are at risk of 
developing cervical cancer with 493,243 new cases being diagnosed with invasive 
cervical cancer worldwide each year, 80% of which were from developing countries 
(Castlellsagué et al., 2007). It is responsible for over 250,000 deaths representing 
nearly 10% of all cancers in women in 2005 (WHO, 2006). Because the disease 
progresses over many years, it is estimated that up to 7 million women worldwide 
may have precancerous conditions that need to be identified and treated (Baseman 
and Koutsky, 2005).  
 
Figure 1.1 Ranking of incidence of cervical cancer in comparison to other 
cancers in women with all ages by country. 
Adapted from Castlellsagué et al. (2007).  
Key represent ranking of incidence.  
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1.1.1 Incidence and mortality rates 
 
Mortality rates are substantially lower than incidence rates. Worldwide, the 
age-standardized incidence rates (ASR) for cervical cancer is 16.2 per 100,000 and 
the mortality rate is 9.0 per 100,000 populations (Parkin et al., 2008). In South-
Eastern Asia (the region where Malaysia belongs to), incidence and mortality rates 
are 18.7 and 10.2, respectively. According to the National Cancer Registry (NCR) 
report (2003), the ASR cancer incidence and mortality rates in Malaysia for the year 
2002 were 15.7 and 8.4 per 100,000 populations, respectively. It occurrence slightly 
increases in the following year (2003) which represents ASR cancer incidence and 
mortality rate of 19.2 and 15.9 per 100,000 populations (NCR, 2004). Table 1.1 and 
1.2 shows the estimated incidence and mortality rates of cervical cancer in Malaysia, 
South-Eastern Asia and the world (WHO, 2007). 
 
Malaysia has a population of 8.49 million women aged 15 years and older 
who are at risk of developing cervical cancer (Castlellsagué et al., 2007). Current 
data indicated that 1,492 women were diagnosed with cervical cancer and 766 die 
from the disease every year (WHO, 2007). Its remains the second most frequently 
reported cancers among women after breast cancer, where it stands at 12.0% of total 
cancer cases recorded in 2002 (NCR, 2003) and 12.9% the following year (NCR, 
2004). As reported by Malaysian Medical Association (MMA) in 2002, nearly 10.5% 
of death among women in government hospitals is due to cancer of the cervix.   
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Table 1.1 Incidence of cervical cancer in Malaysia, South-Eastern Asia and the 
World. 
 
Indicator 
 
Malaysia South-Eastern 
Asia 
World 
Crude incidence rate 
Age-standardized incidence rate 
Cumulative risk (%) 
Age period 0-64 years 
Standardized incidence ratio (SIR) 
Annual number of new cancer cases 
13.1 
15.7 
1.2 
 
95 
1,492 
15.9 
18.7 
1.5 
 
112 
42,538 
16 
16.2 
1.3 
 
100 
493,243 
Rates are per 100,000 women. 
Standardized rates are estimated using the direct method and the World population as the reference. 
  
 
Table 1.2 Mortality of cervical cancer in Malaysia, South-Eastern Asia and the 
World. 
 
Indicator 
 
Malaysia South-Eastern 
Asia 
World 
Crude mortality rate 
Age-standardized mortality rate 
Cumulative risk (%) 
Age period 0-64 years 
Standardized mortality ratio (SMR) 
Annual number of deaths 
6.8 
8.4 
0.6 
 
92 
766 
8.4 
10.2 
0.8 
 
112 
22,594 
8.9 
9 
0.7 
 
100 
273,505 
Rates are per 100,000 women. 
Standardized rates are estimated using the direct method and the World population as the reference. 
 
 
The incidence and mortality rates vary between different age groups. The 
schematic diagram for the age-specific incidence and mortality rates of cervical 
cancer in Malaysia as compared to estimates for South-Eastern Asia and the World 
are shown in Figure 1.2 and 1.3 (WHO, 2007). The graph showed that the incidence 
and mortality rates of women in Malaysia increased at age above 55, contrary to the 
rates in South-Eastern Asia and the World. The reasons for this difference may due 
to the late screening for the cervical cancer or ineffective screening program among 
Malaysian women.  
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Figure 1.2 Age-specific incidence rates of cervical cancer in Malaysia as compared to 
estimates for South-Eastern Asia and the World. 
 
 
 
 
Figure 1.3 Age-specific mortality rates of cervical cancer in Malaysia as compared to 
estimates for South-Eastern Asia and the World. 
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There are some variations of ASR between the major ethnics groups in 
Malaysia. As reported in the first (2003) and second (2004) report of NCR, for the 
year 2002, Chinese women have the highest ASR with 33.6 per 100,000, followed by 
Indian women with 27.7 per 100,000 population and Malay women with 12.6 per 
100,000. In 2003, Chinese women still lead with ASR of 28.8 per 100,000, followed 
by Indians and Malay women with 22.4 and 10.5 per 100,000 women respectively. 
 
In term of economical status, there is a big difference in the incidence and 
mortality rates of cervical cancer between developed and developing countries. 
According to Parkin and Bray (2006), the hardest-hit regions are among the worlds 
poorest. Central and South America, the Caribbean, sub-Saharan Africa, and parts of 
Oceania and Asia have the highest incidence rates of over 30 per 100,000 women. 
These rates are lower compared with the figures for North America and Europe 
which is no more than 10 per 100,000 women. In 2008, Parkin and coworkers 
reported that the highest estimated ASR incidence rates (per 100,000 populations) for 
the year 2002 were observed in the Melanesian populations. These countries include 
Solomon Islands (42.8), Papua New Guinea (40.4) and Fiji (33.4). Lowest ASR 
incidence rates were observed in China (6.8), Australia (6.9) and Japan (8.0).  
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1.1.2 HPV Burden in Women 
 
HPV prevalence among countries may vary considerably across studies. This 
is due to the insufficient degree of geographical coverage and sample size, diversity 
in the techniques used for HPV detection and variety methods used for estimating 
HPV type-specific prevalence (Giuliano et al., 2008, Bosch et al., 2008). Worldwide 
and regional estimates of HPV type-specific prevalence in women with and without 
cervical lesions have been estimated from highly standardised multicentric studies. 
For example,  International Agency for Research on Cancer (IARC) of cervical 
cancer series (Franceschi, 2005), IARC HPV prevalence surveys (Maucort-Boulch et 
al., 2008) as well as from the wider meta-analyses of all published data (Bae et al., 
2008, Bao et al., 2008a;b, Bhatla et al., 2008). 
 
The adjusted global prevalence of HPV infection was 10.41% based on a 
meta-analysis of 78 studies of women with normal cytology around the world 
(Burchell et al., 2006). In the same year, Clifford and co-workers reported that the 
overall HPV-DNA prevalence in invasive cervical cancer was 96%, based on pooled 
analysis of 12 studies conducted in 25 countries (3,085 cases). The prevalence of 
HPV types that cause cervical cancer; HPV-16 (53.5%), -18 (17.2%), -45 (6.7%), -31 
(2.9%), -33 (2.6%), and other high-risk types; -52, -58, -35, -59, -56, -39, -51, -73, -
68 and -66 (15-20%) (Clifford et al., 2006).  
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HPV prevalence in women with different cytological diagnosis in Malaysia, 
South-Eastern Asia and the world are shown in Table 1.3 (WHO, 2007). Complete 
data is not yet available on the HPV burden in the general population of Malaysia. 
However, according to the South-Eastern Asia HPV prevalence estimate, about 6.2% 
of women in the general population are estimated to harbour cervical HPV infection 
at any given time (Castlellsagué et al., 2007). 
 
Table 1.3 Burden of HPV in women with and without cervical disease. 
 
Malaysia South-Eastern Asia World  
No. 
tested 
HPV prev.a % 
(95% CIb) 
No. 
tested 
HPV prev.a % 
(95% CI b) 
No. 
tested 
HPV prev.a % 
(95% CI b) 
 
Normal  
 
LGSIL 
 
HGSIL 
 
ICC 
 
- 
 
- 
 
- 
 
23 
 
- 
 
- 
 
- 
 
95.7  
(78.1-99.9) 
 
4,194 
 
27 
 
207 
 
1,090 
 
6.2  
(5.5-6.9) 
33.3  
(16.5-54.0) 
61.8  
(54.8-68.5) 
92.1 
(90.3-93.6) 
 
157,879 
 
8,640 
 
7,094 
 
14,595 
 
10.0 
(9.8-10.1) 
71.6 
(70.6-72.5) 
84.9 
(84.1-85.7) 
87.2 
(86.7-87.8) 
The samples for HPV testing come from cervical specimens (fresh / fixed biopsies or 
exfoliated cells). 
aPrev. = prevalence; bCI = confidence interval 
 
  
Domingo and coworkers (2008) reported that, HPV-16 and -18 are the two 
most common HPV types in Malaysia (excluding East Malaysia), which contribute 
73.9% and 65.2% of total HPV prevalence, respectively. HPV-31 contributes 13% 
followed by HPV-33, 4.3% in a total of 23 cases of cervical cancer. 
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1.2 HPV and Cervical Cancer 
 
HPV infection is now a well-establish cause for the development of a variety 
of epithelial lesions, which range in severity from benign warts to invasive cervical 
cancer (Tristram and Fiander, 2007). More than 90% of invasive cervical cancer 
specimens contain HPV DNA, however, approximately 5% of cervical carcinomas 
may be unrelated to HPV infection (Janicek and Averette, 2001, Bhatla et al., 2008).  
 
Persistent infection with one of 15 high-risk HPV types is considered a 
necessary cause of cervical cancer and are found in the vast majority of cervical and 
anogenital cancers, including vaginal, vulvar, penile and anal cancers (Winters et al., 
2006, Wu et al., 2006). Nearly all occurrences of cervical cancer are linked to HPV-
16 and -18 (Gilson and Mindel, 2001). HPV-16 is the most prevalence of all of the 
high-risk types and it is detectable in more than 50% of all cervical cancer cases 
(Peitsaro et al., 2002, Middleton et al., 2003, Harper, 2004). On the other hand, 
according to Remmerbach et al., (2004) HPV-18 is found in almost 15% of the total 
cases of cervical cancer. Almost 10% of women with HPV-16 infection and 5% with 
HPV-18 infection developed CIN 3 within 36 month. According to Khan and 
coworkers (2005), women who were HPV-DNA negative at enrolment developed a 
1% cumulative incidence for CIN 3 or cervical cancer at 3 years of follow up. As 
continuation, they said at 10 years follow up, 17% of the women who were infected 
with HPV-16 at enrolment and 14% of those infected with HPV-18 at enrolment had 
developed CIN 3 or higher (Khan et al., 2005).  
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HPV-16 and HPV-18 account for 70% of cervical cancer cases, 41–67% of 
high-grade squamous intraepithelial lesion (HGSIL), 16–32% of low-grade 
squamous intraepithelial lesion (LGSIL) and 6–27% of atypical squamous cells of 
undetermined significance (ASCUS), based on the meta-analysis study worldwide. 
These proportions are broadly similar for all global regions, and highlight the 
increasing importance of HPV-16/-18 with increasing lesion severity (Parkin et al., 
2008). 
 
 HPV can produce infection that may be latent and progressive to 
malignancy. It means once cervical cells are infected, abnormalities can progress or 
regress along a spectrum of disease. Through microabrasions, virus is introduced into 
the basal layer of the stratified squamous epithelium. It takes 1 to 10 years for HPV 
to change normal cell into becoming severe dysplasia and invasive carcinoma 
through viral proliferation, genomic integration, and oncogenic transformation. 
Although the majority of HPV infections regress following initial infection, 
persistent HPV infection remains a serious concern because it may lead to cervical 
cancer (Baseman and Koutsky, 2005). Expression of viral non-structural proteins 
stimulates cellular proliferation, resulting in latent and subclinical infection, 
condyloma, or dysplasia. The cytological hallmark of HPV infection is when infected 
cells display koilocytosis. The characteristics of koilocytosis is when ‘halo’ cells 
appear, nuclei enlarged, irregular chromatin, perinuclear clearing, and a cytoplasmic 
border that varies from thick to thin. Each koilocyte contained approximately 50-100 
virions (Paavonen, 2007). The schematic of the progression from HPV infection to 
invasive cancer are shown in Figure 1.4. 
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Figure 1.4 Schematic of the progression from HPV infection to invasive cancer. 
 Modified from Park (2008), Moscicki et al. (2006) and Palefsky (2001).  
 
*HPV, Human papillomavirus; LGSIL, Low-Grade Squamous Intraepithelial Lesion; 
HGSIL, High-Grade Squamous Intraepithelial Lesion; and CIN, Cervical Intraepithelial 
Neoplasia.   
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1.2.1 HPV Genome 
 
HPV belongs to the Papillomaviridae family, a relatively small with 55 nm in 
diameter, non-enveloped virus with circular double stranded DNA of approximately 
8 kb in size (Tristram and Fiander, 2007). The genome can be divided into three 
regions: an upstream regulatory region (URR), an early (E) and a late (L) region 
(Villa, 2006). HPV has eight genes, known as open reading frames (ORFs), which 
encode for functional viral proteins (Figure 1.5). The upstream regulatory region 
(URR) contains the p97 core promoter along with enhancer and silencer sequences. It 
regulates DNA replication by controlling the transcription of the ORFs and contains 
the highest degree of variation in the viral genome (Braaten and Laufer, 2008).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Schematic presentation of the HPV genome showing the arrangement 
of the early protein (E1-E7), late proteins (L1-L2) and the upstream regulatory 
region (URR).  
Adapted from Munoz et al., (2006).  
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1.2.1.1 Function of viral proteins 
 
The viral proteins are named after their encoding open reading frame (ORF)s; 
DNA sequence that does not contain a stop codon in a given reading frame. For over 
the past decades, the L1 ORF has been used for genotyping and identification of new 
HPV genotypes because it contained the most conserved gene within the HPV 
genome. A summary of the key functions of each protein is given in Table 1.4 (Burd, 
2003). The early (E) region codes for regulatory functions engaged in genome 
persistence, DNA replication and activation of the lytic life cycle (Burd, 2003). E2 is 
a transcriptional repressor of E6 and E7. The loss of this ORF during viral integration 
in anogenital neoplasia results in an upregulation of E6 and E7 expression. The two 
viral capsid proteins L1 and L2 are encoded by ORFs within the late region (Vetter 
and Geller, 2007). 
 
Table 1.4 Summary of the key function of proteins encoded by HPV.  
ORFs 
 
Protein function 
L1 
 
 
L2 
 
E1 
 
E2 
 
E4 
 
E5 
 
E6 
 
E7 
Major viral capsid protein; viral conformation eg. Viral-like particles 
(VLPs) 
 
Minor viral capsid protein; viral genome encapsidation 
 
Viral replication; maintain episome 
 
Regulates viral transcription and replication 
 
Interacts with cytoskeletal proteins 
 
Down regulation of MHC class 1 molecules 
 
Oncoproteins; binds to tumour suppressor protein p53 
 
Oncoproteins; binds to tumour suppressor protein retinoblastoma (Rb) 
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1.2.1.2 Types 
 
HPV was first recognized as the cause of cutaneous warts (plantar warts, 
common warts, and flat warts) and it depends on the type of HPV infection (Burd, 
2003). One hundred and eighteen types of HPV have been recognized based on 
nucleotide sequence homology (Burd, 2007). More than 40 HPV-types have been 
isolated from genital lesions (Tristram and Fiander, 2007). Munoz et al., (2003) had 
classified genital HPV into 4 groups based on their association with cervical cancer 
and precursor lesions from multiple countries; 15 HPV types have been classified as 
high-risk (HR) for development of cervical cancer, 3 have been classified as probable 
high-risk (PHR), 12 have been classified as low risk (LR) and 3 are considered to 
have undetermined risk (UR) (Table 1.5).  
 
Table 1.5 Classification of HPV types by cervical oncogenecity.  
Risk classification 
 
HPV types 
 
High-risk  
 
Probable high-risk  
 
Low risk  
 
Undetermined risk 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 
 
26, 53, 66 
 
6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108 
 
34, 57, 83 
 
 
Multiple HPV types can be found co-existing within the same lesion and may 
be though as multiple infections. Types 6 and 11 are the most common LR types 
found in approximately 90% of warts (Bernard, 2005). High-risk (HR) HPV types 
are associated with anogenital neoplasia and have been reported in 99.7% of cervical 
cancers worldwide (Tristram and Fiander, 2007).  
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1.2.2 Molecular basis of oncogenesis of HPV-induced cancer 
 
 
HPV contributes to neoplastic progression predominantly through the action 
of two viral oncoproteins; E6 and E7 under the regulation of the E2 gene product 
(Wise-Draper and Wells, 2008). These two oncoproteins have been shown to posses 
transforming ability when transfected into cell lines (Smotkin and Wettstein, 1987). 
The mechanism by which some viral infection remain low risk and some are high 
risk for developing high grade CIN or invasive cancer are different. In HPV infected 
lesions, the low risk viral DNA remains structurally as episomes. In the invasive 
cancers, the viral genome is usually found integrated into chromatin material of the 
host nucleus (Munoz et al., 2003). In brief, many of current research shows that HPV 
interacts with host proteins to deregulate the cell cycle (Cordano et al., 2008). 
 
High-risk HPV E6 and E7 products interfere with critical cell cycle pathways 
which are governed by the tumour suppressor proteins (p53) and retinoblastoma 
protein (pRB), resulting in the accumulation of DNA damage and the development of 
cervical cancer (Kaufmann et al., 2002).  
 
The HPV E6 gene product binds to p53 tumor suppressor gene and induces 
p53 degradation via a cellular enzyme ubiquitin ligase. As a consequence, the normal 
activities of p53 which govern G1 process, apoptosis, and DNA repair can be 
suppressed. LR-HPV E6 proteins do not bind to p53 at detectable levels and have no 
effect on p53 stability in vitro (Burd, 2003).  
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The HPV E7 gene product binds to the retinoblastoma gene product (pRB) 
and altering its phosphorylation state and inactivates the protein. This binding 
disrupts the complex between pRB and the cellular transcription factor E2F-1, 
resulting in the liberation of E2F-1. Specifically, pRB normally binds with the 
transcription factor E2F, which functions in cell cycle progression from G1 to the S 
phase following interaction with cyclin and cyclin-dependent kinases. The E7 gene 
product can also associate with other mitotically interactive cellular proteins such as 
cyclin E resulting in stimulation of cellular DNA synthesis and cell proliferation. The 
E7 protein from LR-HPV types binds pRB with decreased affinity (Janicek and 
Averette, 2001). The illustration of the oncogenesis of HPV E6 and E7 genes at 
cellular event and their mechanisms is shown in Figure 1.6.  
 
The ability of binding and inactivation activity against p53 and pRB can also 
be found in gene products of other DNA tumor viruses such as SV40 (large T 
antigen; involved in viral genome replication and regulation of host cell cycle) and 
Adenovirus (E1A and E1B; independent transcription units in E1 region) (Janicek 
and Averette, 2001).  
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Figure 1.6 The illustration of the oncogenesis of HPV E6 and E7 genes at 
cellular event.  
Adapted from Burd (2003).  
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1.2.3 Epidemiology of HPVs 
 
 
Transmission of HPV occurs predominantly by sexual transmission 
(penetrative genital or anal contact). HPV is very resistant to heat, desiccation and 
nonsexual transmission via fomites can also occur, such as by prolonged exposure to 
shared contaminated clothing (Baseman and Koutsky, 2005). However, there is little 
or no evidence to suggest that HPV can be transmitted by nonsexual routes. 
 
An individual is at a greater risk of becoming infected with HPV if he or she 
has had multiple sexual partners at any time or is the partner of someone who has 
had multiple sexual partners (Schiffman and Castle, 2003, Burd, 2003).  
 
 HPV infection is most common in sexually active young women, 18 to 30 
years of age (Syrjanen et al., 2008a, de Sanjose et al., 2008). There is a sharp 
decrease in prevalence after 30 years of age. However, cervical cancer is more 
common in women older than 35 years, suggesting infection at a younger age and 
slow progression to cancer (Domingo et al., 2008). Meta-analysis of data on cervical 
infection demonstrated an overall prevalence of 10-12% in adult women; highest in 
younger women (<30 years) (Franceschi, 2005, Syrjanen, 2008, Syrjanen et al., 
2008b).  
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1.2.3.1 Risk factors  
 
Two factors enhancing the oncogenic power of HPV have already been 
identified: smoking and oral contraceptives. It has been proven that women with 
oncogenic HPV and minimally abnormal Papanicolaou smears who smoke were up 
to three times more likely to be diagnosed with CIN 3 than nonsmokers (McIntyre-
Seltman et al., 2005). A recently published meta-analysis and a large cohort study 
showed independently that use of oral contraceptives (OC) leads to an increased 
relative risk (RR) of cervical cancer. The RR increased with duration of OC use and 
is 1.90 after 5 years or more (95% CI: 1.69-2.13) and decreased upon cessation of 
OC use and was normal again 10 years later. Longstanding OC use enhances human 
papillomavirus (HPV) transcription and decreases HPV clearance, resulting in more 
frequent persistence of HPV, an increase of cervical intraepithelial neoplasia, and an 
increased RR of cervical cancer (Schmeink et al., 2008).  
 
Other determinants of the progression of HPV infection to cervical cancer 
relate to a woman’s immune status. Those with an immune system compromised as a 
result of malnutrition are also at increased risks from cervical dysplasia. Women in 
the lowest serum retinol quartile were at an increased risk of CIN I compared with 
women in the highest quartile (Yeo et al., 2000). Risk of type-specific, persistent 
HPV infection was lower among women reporting intake values of vitamin C in the 
upper quartile compared with those reporting intake in the lowest quartile (Giuliano 
et al., 2003). A statistically significantly lower level of alpha-tocopherol was also 
observed in the blood serum of HPV-positive patients with cervical intraepithelial 
neoplasia. The risk of dysplasia was four times higher for an alpha-tocopherol level 
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<7.95 mmol/l (Kwaśniewska et al., 1997). Studies by Piyathilake et al., (2004) have 
shown that CIN development can be prevented by improving folate status in subjects. 
Meanwhile, women who are co-infected with the human immunodeficiency virus 
(HIV) are at increased risk for malignant progression in the cervix due to the low 
CD4+ T cell counts in the body (Yamada et al., 2008, Minkoff et al., 2008).  
 
Others factors such as hormonal influences (pregnancy) (Selleret and 
Mathevet, 2008), other STDs (e.g., Chlamydia trachomatis, HSV-2) (Sasagawa et 
al., 2000, Hara et al., 1997, Hawthorne et al., 2005), or genetic predisposition and 
immunosuppressive chemotherapy (Venturoli et al., 2008, Ab Hamid and Wastie, 
2008), appear to be at an increased risk of HPV progression and can lead to cervical 
cancer. Some studies had related that high parity, race, alcohol consumption, 
circumcision, and low socioeconomic status as significant risk factors for cervical 
cancer (Safaeian et al., 2008, Mariani et al., 2008, Madsen et al., 2008, Morris, 2007, 
Svare et al., 2002). However, none of these have consistently been shown to be 
significant independent risk factors. The number of studies that follow women 
longitudinally is still insufficient to provide solid data on the relative importance of 
these risk factors. Persistence of infection is more common with the high-risk 
oncogenic HPV types and is an important determinant in the development of cervical 
cancer (Moscicki et al., 2006).  
 
 
 
 
